ABM Industries heads into its September 8 earnings report with the market still unconvinced that its messy ERP rollout is behind it.
The positioning data offers little drama here. Short interest is a modest 3.2% of free float — down roughly 25% over the past month as some bears have covered — and the borrow market is entirely relaxed, with availability running at over 1,500%, meaning shares to lend dwarf the existing short position by a wide margin. Borrowing costs have also eased, recently dipping below 0.35%. Options are equally calm: the put/call ratio of 0.14 is barely above its 20-day average and far from any extreme. The stock itself has drifted down about 4% over the past month, closing at $47.05, and the week has been essentially flat. Nothing in the positioning screams conviction either way.
The real debate is fundamental. The bull case rests on a straightforward recovery thesis: transformation costs tied to the ELEVATE initiative are expected to decline through fiscal 2026 and 2027, which would restore free cash flow conversion from the negative territory it recently hit — a dramatic reversal from the 54% EBITDA conversion rate seen just a year prior. Office vacancy stabilisation could also lift the Business and Industry segment. Bears, however, point to three consecutive quarters of ERP disruption, extended days sales outstanding, and forecasts that organic growth and returns on invested capital remain depressed for the foreseeable future. Analyst sentiment reflects that stalemate: Baird lifted its target to $48 in June while keeping a Neutral rating, and the consensus mean target of around $52 implies roughly 11% upside from current levels — reasonable on paper, but contingent on operational normalisation actually materialising. The most recent cluster of analyst activity, in March, saw multiple firms cut targets following a weak print, with Truist downgrading to Hold.
Insider activity adds a note of caution without being alarming. CEO Scott Salmirs sold just over $2.3 million worth of stock in June under pre-arranged 10b5-1 plans, and several other senior executives have also sold in recent months. No open-market purchases appear in the record. Pre-planned sales carry less signal than discretionary ones, but the absence of any buying from management into what is supposedly a recovery year is worth noting.
The September 8 print will test whether ABM can demonstrate that EBITDA conversion is genuinely turning — and whether cash flow is moving back toward the levels the recovery story requires.
See the live data behind this article on ORTEX.
Open ABM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
